Hansa Medical publishes financial information from its prospectus regarding the new share issue

23 May 2011, 14:30

Regulatory information

On 12 May 2011, Hansa Medical’s annual meeting of shareholders resolved to execute a new share issue of SEK 29 million, with preferential rights to Hansa Medical’s shareholders. Hansa Medical, today, makes official those details which have not been previously published, but which are now available in the new share issue prospectus.

Financial position as at 31 March 2011
The Group’s cash and bank balances amounted at 31 March to just under MSEK 0.1 and equity amounted to MSEK 27.2. Net liabilities amounted to MSEK 9.4, of which MSEK 7.8 was comprised of bridge financing in the form of loans. Short-term liabilities amounted to MSEK 2.3 and were comprised primarily of accounts payable. The attached tables show the Group’s net liabilities as at 31 March 2011.

Files

wkr0001.pdf

For further information, please contact:
Emanuel Björne, CEO Hansa Medical AB
Mobile: +46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Hansa Medical is a biopharmaceutical development company focused on inflammation. The company develops innovative biopharmaceuticals and diagnostics in partnership with major companies with market presence as well as under full Hansa Medical management. At present, three primary product candidates are in development; IdeS, anti-alpha-11 and HMD-301. Novel research projects and product candidates are generated through academic collaborations and in-house development. Hansa Medical is publicly traded at NASDAQ OMX First North under ticker symbol HMED. Remium AB is Certified Adviser to Hansa Medical.